| Name | Title | Contact Details |
|---|---|---|
Kevin Duvall |
ARPA-H Chief Information Officer | Profile |
Kevin Duvall |
Acting Chief Technology Officer and Chief Information Officer | Profile |
We are advocates, not just providers. Leading health plans and patients to better outcomes through a broad range of medication therapy management (MTM) programs. Empowering connections that matter. Mirixa is the leading provider of MTM and targeted, pharmacist-delivered services to health plans. An MTM pioneer, we`ve been building connections since 2006 - harnessing the knowledge and skills of pharmacists to engage more patients and deliver measureable results. We have the largest and most comprehensive pharmacy services network in North America. And we create leading edge programs that reach beyond Medicare Part D compliance, helping health plans of all types deliver a more focused patient experience and positive outcome, while potentially reducing total healthcare costs. Our goal is your goal: to ultimately empower every patient to live a fuller, healthier life.
Clintech Research is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Because your organisation needs certainty when testing for Covid-19
Sojournix is a clinical stage pharmaceutical company focused on creating new medicines to improve the treatment of women’s health and neuroendocrine disorders.
Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.